Core Insights - Lepu Biotech's MRG006A, a targeted GPC3 antibody-drug conjugate (ADC), has successfully completed the first patient enrollment in a Phase II clinical trial for advanced hepatocellular carcinoma (HCC), marking it as the first GPC3 ADC to enter this stage globally [1][2] - MRG006A utilizes Lepu Biotech's Hi-TOPi ADC technology platform, which allows for precise targeting of GPC3-positive tumor cells, thereby releasing toxins specifically within the tumor to achieve targeted cell destruction [1] - GPC3 is a cancer embryonic antigen that is highly expressed in 70%-80% of HCC cases but has minimal expression in normal tissues, making it a promising target for precision therapy [1] Clinical Development - The Phase I clinical trial of MRG006A showed promising results, with significant tumor shrinkage observed in GPC3-positive patients during the dose-escalation study, indicating strong therapeutic potential [2] - The advancement of MRG006A into Phase II clinical research represents a significant breakthrough in Lepu Biotech's ADC pipeline and has the potential to address unmet clinical needs in HCC treatment [2]